How to Use the New European Academy of Neurology/Movement Disorder Society European Section Guideline for Invasive Therapies in Parkinson's Disease

Mov Disord Clin Pract. 2024 Mar;11(3):209-219. doi: 10.1002/mdc3.13962. Epub 2024 Jan 12.

Abstract

Background: The decision to choose invasive treatments for Parkinson's disease (PD) is complex and needs careful consideration.

Objectives: Although the recommendations of the European Academy of Neurology/Movement Disorder Society European Section guideline for invasive therapies of PD are useful, the different clinical profiles of people with PD who seek advice for possible invasive therapy need further attention.

Methods and results: Here we describe 8 clinical standard situations of people with PD unsatisfied with their current oral treatment where invasive therapies may be considered. These are PD patients presenting with the following symptoms: (1) severe motor fluctuations, (2) beginning of levodopa-responsive fluctuations, severe tremor at (3) young or (4) advanced age, (5) impulse control disorders and related behavioral disorders, (6) hallucinations and psychosis, (7) minimal cognitive impairment or mild dementia, and (8) patients in need of palliative care. For some of these conditions, evidence at lower level or simple clinical considerations exist.

Conclusions: There are no one-fits-all answers, but physician and patient should discuss each option carefully considering symptom profile, psychosocial context, availability of therapy alternatives, and many other factors. The current paper outlines our proposed approach to these circumstances.

Keywords: Parkinson's disease; clinical pathway; infusion therapies; surgical interventions.

Publication types

  • Review

MeSH terms

  • Cognitive Dysfunction*
  • Humans
  • Levodopa / therapeutic use
  • Neurology*
  • Parkinson Disease* / therapy
  • Tremor

Substances

  • Levodopa